KCNJ13 (Potassium Voltage-Gated Channel Subfamily J Member 13) is a Protein Coding gene. Diseases associated with KCNJ13 include Snowflake Vitreoretinal Degeneration and Leber Congenital Amaurosis 16. Among its related pathways are Collagen chain trimerization and Dopamine-DARPP32 Feedback onto cAMP Pathway. KCNJ13 encodes a member of the inwardly rectifying potassium channel family of proteins. Members of this family form ion channel pores that allow potassium ions to pass into a cell. The encoded protein belongs to a subfamily of low signal channel conductance proteins that have a low dependence on potassium concentration. Mutations in KCNJ13 are associated with snowflake vitreoretinal degeneration. Alternate splicing results in multiple transcript variants.

Optimal working dilutions should be determined experimentally by the investigator. Suggested starting dilutions are as follows: WB 1:500-2000 ELISA 1:5000-20000.

IRK13 Polyclonal Antibody product listed herein is for research use only and is not intended for use in human or clinical diagnosis. Suggested applications of our products are not recommendations to use our products in violation of any patent or as a license. We cannot be responsible for patent infringements or other violations that may occur with the use of this product.

Find more details at https://www.abbkine.com/product/irk13-polyclonal-antibody-abp58966/

Abbkine Scientific Co., Ltd. was founded by a number of scientists and marketing experts in the field of life science in California in 2012. With growing demands from Asia Pacific, it move its headquarters to China. Combining cutting edge technology from United States with China's manufacturing engineering and cost advantages, we aim to provide innovative, high quality assay kits, recombinant proteins, antibodies and other research tools to accelerate life science fundamental research, drug discovery, etc.